List of Scenesse drug patents

Scenesse is owned by Clivunel Inc.

Scenesse contains Afamelanotide.

Scenesse has a total of 2 drug patents out of which 0 drug patents have expired.

Scenesse was authorised for market use on 08 October, 2019.

Scenesse is available in implant;subcutaneous dosage forms.

Scenesse can be used as increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (epp).

Drug patent challenges can be filed against Scenesse from October, 2023.

The generics of Scenesse are possible to be released after 11 March, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10076555 CLIVUNEL INC Methods of inducing melanogenesis in a subject
Feb, 2025

(2 years from now)

US8334265 CLIVUNEL INC Method of treatment of photodermatoses
Mar, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Oct 8, 2026
New Chemical Entity Exclusivity (NCE) Oct 8, 2024

Drugs and Companies using AFAMELANOTIDE ingredient

NCE-1 date: October, 2023

Market Authorisation Date: 08 October, 2019

Treatment: Increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (epp)

Dosage: IMPLANT;SUBCUTANEOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in